Strategic CDMO Takara Bio serves as a contract development and manufacturing organization in regenerative medicine, cell therapy, and gene therapy, presenting a growth channel for pharma and biotech partners seeking end-to-end development and manufacturing capabilities.

Genomics Leadership With Japan’s largest next-generation sequencing capability and a broad catalog of about ten thousand gene and cell engineering products, there are cross-sell opportunities for custom sequencing, analysis, and related reagents to researchers and biotech firms.

Global Footprint A multinational network including offices and affiliates in the US, Europe, Korea, India, Beijing, Dalian, and Japan enables regional sales strategies, localized support, and partnerships across high-growth markets.

Vaccines Opportunity Active involvement in coronavirus vaccine development demonstrates capability in cutting-edge gene-editing approaches, suggesting collaboration potential with vaccine developers or translational programs needing plasmid design, validation, or manufacturing support.

EstablishedTrackRecord Historical milestones as Japan’s first to market restriction enzymes and PCR, along with a sizable revenue range, position Takara Bio as a trusted supplier for researchers, enabling targeted outreach to labs upgrading to high-value analyses and CDMO services.